CHAMPIONS ONCOLOGY, INC.
CSBR evidence brief
What we can confirm
- BioSniper Score:
- 3.7 / 10
- Market Cap:
- $68.6M
- Cash Runway:
- 26.6 mo
What it means
What to watch
Prepared research question
What matters most for CSBR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CSBR
Champions Oncology, Inc. (CSBR) is a technology-enabled oncology research organization providing clinically relevant tumor models, translational solutions, and a bioinformatics platform (Lumin) to support drug discovery and development.
Key risk: Net loss reversal
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jul 31, 2026.
Champions Oncology, Inc. (CSBR) is a technology-enabled oncology research organization providing clinically relevant tumor models, translational solutions, and a bioinformatics platform (Lumin) to support drug discovery and development.
- Record annual revenue of $59 million for the fiscal year ended April 30, 2026 [news · 2026-07-27].
- Cash & equivalents of $4.4M, total revenue of $15.2M, net income of -$0.4M, and shareholders' equity of $3.9M as of 2026-07-31 [sec].
- Expanded integrated radiopharmaceutical development platform with in-house SPECT/CT imaging capabilities [news · 2026-09-01].
- Presented eight studies at AACR 2026 on predicting drug response and resistance using clinically relevant models [news · 2026-04-10].
- Accumulated deficit of approximately $81.1 million as of April 30, 2026 [sec_mda · as of 2026-07-27].
What works
- Record annual revenue of $59 million and fourth consecutive quarter of positive adjusted EBITDA demonstrate improving operational performance [news · 2026-07-27].
- Expansion of radiopharmaceutical development platform with in-house SPECT/CT imaging adds new molecular imaging capabilities to its service offerings [news · 2026-09-01].
- Lumin Bioinformatics platform leverages a large Datacenter with analytics and AI to provide a robust tool for computational cancer research [sec_mda · as of 2026-07-27].
What to weigh
- Net loss of approximately $1.2 million for the year ended April 30, 2026, compared to net income of $4.7 million in the prior year [sec_mda · as of 2026-07-27].
- Accumulated deficit of approximately $81.1 million and negative working capital of $703,000 as of April 30, 2026 [sec_mda · as of 2026-07-27].
- Cash flow from operations used approximately $4.5 million during the twelve months ended April 30, 2026 [sec_mda · as of 2026-07-27].
- Cash & equivalents of $4.4M as of 2026-07-31 [sec] is relatively low compared to annual revenue, indicating limited liquidity.
From the filings
Quoted directly from source documents.
Record annual revenue of $59 million
“Champions Oncology Reports Record Annual Revenue of $59 Million”
News · July 27, 2026
Net loss of $1.2 million for fiscal year ended April 30, 2026
“For the years ended April 30, 2026 and 2025, the Company had a net loss of approximately $1.2 million and net income of approximately $4.7 million, respectively.”
SEC MD&A · July 27, 2026
Accumulated deficit of $81.1 million as of April 30, 2026
“As of April 30, 2026, the Company had an accumulated deficit of approximately $81.1 million, negative working capital of $703,000 and cash of $4.9 million.”
SEC MD&A · July 27, 2026
Expansion of radiopharmaceutical platform with SPECT/CT imaging
“Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging”
News · September 1, 2026
Risks & what to watch (3)›
Key risks
- Net loss reversal — Company swung from net income of $4.7M (FY2025) to net loss of $1.2M (FY2026) [sec_mda · as of 2026-07-27].
- High accumulated deficit — Accumulated deficit of $81.1M as of April 30, 2026, with negative working capital [sec_mda · as of 2026-07-27].
- Low cash reserves — Cash & equivalents of $4.4M as of 2026-07-31 [sec] may limit ability to fund operations or strategic initiatives.
What to watch
- First quarter financial results for FY2027 to be announced on September 10, 2026 [news · 2026-09-04].
- Continued adoption of Lumin Bioinformatics platform and its impact on revenue growth [sec_mda · as of 2026-07-27].
- Progress of radiopharmaceutical development platform expansion and any new partnerships or licensing deals [news · 2026-09-01].
- Ability to achieve sustained positive adjusted EBITDA and return to net profitability [news · 2026-07-27].
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run CHAMPIONS ONCOLOGY, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHAMPIONS ONCOLOGY, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
26.6 months
D/E 7.41
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$32.8M
| Holder | Shares | Value |
|---|---|---|
| battery management corp. | 2,421,673 | $13.9M |
| nea management company, llc | 1,713,720 | $9.9M |
| tocqueville asset management l.p. | 319,674 | $1.8M |
| vanguard capital management llc | 299,520 | $1.7M |
| morgan stanley | 242,300 | $1.4M |
| renaissance technologies llc | 145,539 | $837K |
| blackrock, inc. | 123,900 | $712K |
| mink brook asset management llc | 111,338 | $640K |
| geode capital management, llc | 77,177 | $444K |
| northern trust corp | 45,932 | $264K |
Showing top 10 of 25 institutional holders of CHAMPIONS ONCOLOGY, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.2%
- Days to cover
- 12.3
- Shares short
- 83,705
- Daily short volume (Jun 17, 2026)
- 34.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CSBR short interestGovernance
Frequently asked questions
What is the AI investment thesis for CHAMPIONS ONCOLOGY, INC.?
Champions Oncology, Inc. (CSBR) is a technology-enabled oncology research organization providing clinically relevant tumor models, translational solutions, and a bioinformatics platform (Lumin) to support drug discovery and development.
Who is the CEO of CHAMPIONS ONCOLOGY, INC.?
Mr. Robert Brainin is the chief executive officer of CHAMPIONS ONCOLOGY, INC. (CSBR).
Where is CHAMPIONS ONCOLOGY, INC. headquartered?
CHAMPIONS ONCOLOGY, INC. (CSBR) is headquartered in Hackensack, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.